 |
|
Finding suggests novel ways to boost vaccination or natural defenses
July 08, 2008Our bodies rely on the production of potent, or 'high affinity', antibodies to fight infection. The process is very complex, yet Sydney scientists have discovered that it hinges on a single molecule, a growth factor, without which it cannot function.
There is much we do not yet understand about our immune system. In simple terms, our bodies produce B cells, which make antibodies, and T cells, which help them. Ways in which these cells operate and interact with each other are still coming to light.
Roughly eight years ago, a new subset of T cells, T follicular helper (TFH) cells, was identified. This important class of T cells operates in specific environments termed 'germinal centres', specialised areas within lymph organs where B cells proliferate to form high affinity antibodies whenever we fight infection. TFH cells play a critical role in that they communicate with, and help activate, B cells.
The novel finding made by Dr Cecile King and PhD student Alexis Vogelzang, from the Garvan Institute of Medical Research in Sydney, was that the molecule interleukin 21 (IL-21) is a growth factor for TFH cells. A paper detailing this finding was published online today in the prestigious international journal Immunity.
A cytokine, or chemical messenger, IL-21 is already well known to immunologists. While its newly identified growth factor role is only one of several functions, that function is fundamental. Without IL-21, the all-important TFH cells could neither develop nor survive.
Dr Cecile King, head of the Mucosal Autoimmunity Group at Garvan, has been investigating the roles of IL-21 for several years. "We already knew that IL-21 was produced by TFH cells and that it was a major initiator of proliferation in B cells," she said. "We were surprised to find that TFH cells not only produce IL-21, they also absolutely need it to survive and they utilise it to function."
"We showed that if you take a mouse genetically deficient in IL-21 and immunise it, you don't get TFH cells and you don't get antibody production. Conversely, if you put IL-21 receptor sufficient, or normal, T cells into the same mouse, where of course the B cells remain abnormal, you recover the normal immune reaction."
"These specialised T cells are thought to be the ones that direct traffic. They are the only ones that can move into the B cell zone and initiate high affinity antibody production."
"Without IL-21, we probably wouldn't be completely immunodeficient, just severely compromised. In addition to the high affinity antibodies we're talking about, our bodies also produce a lot of low affinity antibodies for mopping up infection. That low level response happens around-the-clock and is one of our body's first lines of defence."
"You could say that IL-21 directs the most finely-tuned aspect of our immune response. The highly specialised weaponry developed on-the-spot to target aggressive invaders."
"This finding suggests novel ways to boost vaccination or natural defences."
Research Australia
The novel finding made by Dr Cecile King and PhD student Alexis Vogelzang, from the Garvan Institute of Medical Research in Sydney, was that the molecule interleukin 21 (IL-21) is a growth factor for TFH cells. A paper detailing this finding was published online today in the prestigious international journal Immunity.
A cytokine, or chemical messenger, IL-21 is already well known to immunologists. While its newly identified growth factor role is only one of several functions, that function is fundamental. Without IL-21, the all-important TFH cells could neither develop nor survive.
Dr Cecile King, head of the Mucosal Autoimmunity Group at Garvan, has been investigating the roles of IL-21 for several years. "We already knew that IL-21 was produced by TFH cells and that it was a major initiator of proliferation in B cells," she said. "We were surprised to find that TFH cells not only produce IL-21, they also absolutely need it to survive and they utilise it to function."
"We showed that if you take a mouse genetically deficient in IL-21 and immunise it, you don't get TFH cells and you don't get antibody production. Conversely, if you put IL-21 receptor sufficient, or normal, T cells into the same mouse, where of course the B cells remain abnormal, you recover the normal immune reaction."
"These specialised T cells are thought to be the ones that direct traffic. They are the only ones that can move into the B cell zone and initiate high affinity antibody production."
"Without IL-21, we probably wouldn't be completely immunodeficient, just severely compromised. In addition to the high affinity antibodies we're talking about, our bodies also produce a lot of low affinity antibodies for mopping up infection. That low level response happens around-the-clock and is one of our body's first lines of defence."
"You could say that IL-21 directs the most finely-tuned aspect of our immune response. The highly specialised weaponry developed on-the-spot to target aggressive invaders."
"This finding suggests novel ways to boost vaccination or natural defences."
Research Australia
Antibodies Current Events and Antibodies News RSSNew Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer
Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.
Common Pain Relievers May Dilute Power of Flu Shots
With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.
PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines
Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa.
Study reveals a 'missing link' in immune response to disease
The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.
Breakthrough in industrial-scale nanotube processing
Rice University scientists today unveiled a method for the industrial-scale processing of pure carbon-nanotube fibers that could lead to revolutionary advances in materials science, power distribution and nanoelectronics.
Breakthrough in fight against Hendra virus
There has been a breakthrough in the fight against the deadly Hendra virus following the development of a treatment which shows great potential to save the lives of people who become infected with the virus.
USU scientists report major advance in human antibody therapy against deadly Nipah virus
A collaborative research team from the Uniformed Services University of the Health Sciences (USU), Australian Animal Health Laboratory and National Cancer Institute, a component of the National Institutes of Health, reports a major step forward in the development of an effective therapy against two deadly viruses, Nipah virus and the related Hendra virus.
Caltech researchers show efficacy of gene therapy in mouse models of Huntington's disease
Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.
Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Exploring the final frontier: Disease proposed as major barrier to Mars and beyond
New research published in the Journal of Leukocyte Biology suggests that prolific virulence and growth of bacteria, coupled with reduced production of antibodies could limit future space travel.
More Antibodies Current Events and Antibodies News Articles
 |
Antibodies: A Laboratory Manual by Ed Harlow (Author), David Lane (Author) Introduction to immunochemistry for molecular biologists and other nonspecialists. Spiral. |
 |
Making and Using Antibodies: A Practical Handbook by Gary C. Howard (Editor), Matthew R. Kaser (Editor) Antibodies are an indispensable tool in the study of biology and medicine. Making and Using Antibodies: A Practical Handbook presents techniques in a single, comprehensive source for the production and use of antibodies. It enables researchers to immediately access lab-tested, proven protocols. Written and edited by an elite team of scientists, who have developed and refined many of the methods, this book covers- Commercially available adjuvants designed for the production of antisera in the research setting Methods for the production, purification, and characterization of antibodies Practical guidance to researchers needing to modify antibodies Basic techniques including enzyme-linked immunosorbent assay (ELISA), Western blotting, immunohistochemistry, and flow... |
 |
Monoclonal Antibodies in Biotechnology: Theoretical and Practical Aspects (Cambridge Studies in Biotechnology) by Kenneth C. McCullough (Author), Raymond E. Spier (Author) This volume provides a complete description of the principles, methodologies and applications of monoclonal antibodies, one of the most exciting developments to occur in biotechnology in recent years, and a powerful technology for modern industry and science. The immune system and the role of the antibody are described and full details are given on how the hybridomas are formed, isolated, and maintained in culture such that the required antibody can be produced to a high degree of purity. The authors describe all the methodologies involved, all the reagents and solutions and all the assay conditions required for their production. The material is presented to enable research and development managers to make choices as to which are the most suitable techniques for their requirements. The... |
 |
Antibodies (Two-Disc Special Edition) Starring: Norman Reedus, Christian von Aster, André Hennicke, Waltraud Witte, Konstantin Graudus Directed By: Christian Alvart Studio: Mpi Home Video Release Date: 08/28/2007 Run time: 128 minutes |
 |
Monoclonal Antibodies: Methods and Protocols (Methods in Molecular Biology) by Maher Albitar (Editor) Monoclonal Antibodies: Methods and Protocols examines a collection of state-of-the-art methods that employ monoclonal antibodies in a clinical setting with opening chapters focusing on the gold standard method for generating mouse monoclonal antibodies through hybridoma technology, future methods for engineering recombinant and humanized antibodies, methods for engineering soluble Fc fusion protein, and the use of antibodies and flow cytometry in the quantification of cell signaling proteins. Specific chapters describe how antibodies are used for the diagnosis and classification of hematologic diseases. Subsequent chapters examine the advantages and most recent advances of using bead-based immunoassays, including the ability of bead-based technology to multiplex and analyze several... |
|
Using Antibodies: A Laboratory Manual by Ed Harlow (Author), David Lane (Author) Harvard Medical School, Boston, MA. Introductory textbook for molecular biologists and other nonspecialists. Two-tone format. Previous edition: c1988. Includes nine laminated sheets entitled: Portable Protocols. Hardcover, spiral also available. | |
 |
Therapeutic Antibodies: Methods and Protocols (Methods in Molecular Biology) by Antony S. Dimitrov (Editor) With revenues from the top five therapeutic antibodies accounting for a majority of the recent pharmaceutical sales, the research and development in the field has exploded over the past several years and is expected to grow with new emerging monoclonal antibodies like Numax, Lucentis, Actemra, and others. In Therapeutic Antibodies: Methods and Protocols, leading experts from academic laboratories and biotechnology companies present an extensive set of protocols for the discovery and development of therapeutic antibodies, featuring sections devoted to recombinant antigens, antibody libraries, antibody discovery, antibody engineering, and antibody preclinical development. Written in the highly successful Methods in Molecular Biology™ series format, the chapters contain brief... |
 |
Handbook of Therapeutic Antibodies 3-Volume Set by Stefan Dübel (Editor) In this most comprehensive reference source for the development, production and therapeutic application of antibodies, Volume I contains general chapters presenting established technologies and clinical applications. Volume II provides a look at emerging technologies, new therapeutic concepts, and clinical studies. The third volume features detailed and specific information about each currently approved type of antibody, including the clinical data. A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic. |
 |
Therapeutic Monoclonal Antibodies: From Bench to Clinic by Zhiqiang An (Editor) 70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. First book to address the discovery and development of antibody therapeutics in their entirety. Most chapters contain experimental data to illustrate the principles described in them. Authors provide detailed methodologies that readers can take away with them and use in their own laboratories |
 |
Process Scale Purification of Antibodies by Uwe Gottschalk (Author) Traditional column chromatography dominates current purification technology, and many of the productivity gains that have been achieved have relied on upscaling such devices. However, this comes with a cost penalty and the pharmaceutical industry has reached the point at which further upscaling becomes economically unsupportable. This book offers a broad-based reassessment of old and new purification methods, incorporating an analysis of innovative new trends in purification. The book has wide coverage of different antibody purification strategies and brings together top-tier experts to address problems in process-scale antibody purification. |
| © 2009 BrightSurf.com |